patient
High Risk MDS Non-Transplant Therapies Current Therapies and Clinical Trials Omaha Patient and Family Hybrid Conference 2023
High Risk MDS Non-Transplant Therapies Current Therapies and Clinical Trials with Dr. Prajwal Dhakal
Aplastic Anemia Non-Transplant Therapies and Clinical Trials, from Omaha Patient and Family Hybrid Conference 2023
Amanda Przespolewski, DO
ASH 2022 Update: Aplastic Anemia and PNH
Srinivas Tantravahi, MBBS, MRCP
Dr. Tantravahi has received his medical degree from Guntur medical college, India. He then completed Internal Medicine residency and Hematology and Oncology fellowship training at University of Utah Hospital. His clinical interests include multiple myeloma, stem cell transplantation, and myeloproliferative neoplasm. Research interests are targeted therapy in CML and myeloproliferative neoplasms.
2023 Omaha Patient and Family Hybrid Conference
Here are the session recordings and the presentations for the 2023 Omaha Patient and Family Hybrid Conference.
Living with PNH - Workplace Rights and Responsibilities
Ask the AML Expert
Dr. Salman Fazal will gives a brief AML overview and then answers questions from participants. The question and answer session is recorded here.
Updates from ASH22 on MDS and AML
In this webinar, Dr. Lourdes Mendez discusses research most relevant to patients reported over the past year on the biology and treatment on MDS and secondary AML. These studies were presented at the American Society of Hematology (ASH) 2022 meeting. Research findings are explained along with the potential impact of this research on understanding and treating MDS and AML. This is an advanced scientific presentation. The question and answer session is included in this recording.